BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29633513)

  • 1. ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1.
    Xiong Z; Ye L; Zhenyu H; Li F; Xiong Y; Lin C; Wu X; Deng G; Shi W; Song L; Yuan Z; Wang X
    Mol Oncol; 2018 Jun; 12(6):896-912. PubMed ID: 29633513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.
    Zhang X; Mu X; Huang O; Wang Z; Chen J; Chen D; Wang G
    BMC Cancer; 2022 Mar; 22(1):226. PubMed ID: 35236318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E2F1 transcriptionally regulates CCNA2 expression to promote triple negative breast cancer tumorigenicity.
    Lu Y; Su F; Yang H; Xiao Y; Zhang X; Su H; Zhang T; Bai Y; Ling X
    Cancer Biomark; 2022; 33(1):57-70. PubMed ID: 34366326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
    Hu J; Lai Y; Huang H; Ramakrishnan S; Pan Y; Ma VWS; Cheuk W; So GYK; He Q; Geoffrey Lau C; Zhang L; Cho WCS; Chan KM; Wang X; Rebecca Chin Y
    Br J Cancer; 2022 Jan; 126(1):57-71. PubMed ID: 34718356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E2F1-activated SPIN1 promotes tumor growth via a MDM2-p21-E2F1 feedback loop in gastric cancer.
    Lv BB; Ma RR; Chen X; Zhang GH; Song L; Wang SX; Wang YW; Liu HT; Gao P
    Mol Oncol; 2020 Oct; 14(10):2629-2645. PubMed ID: 32767629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
    Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
    Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
    Zhai Q; Li H; Sun L; Yuan Y; Wang X
    Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
    Zhong G; Lou W; Shen Q; Yu K; Zheng Y
    Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death.
    Beltrán-Anaya FO; Romero-Córdoba S; Rebollar-Vega R; Arrieta O; Bautista-Piña V; Dominguez-Reyes C; Villegas-Carlos F; Tenorio-Torres A; Alfaro-Riuz L; Jiménez-Morales S; Cedro-Tanda A; Ríos-Romero M; Reyes-Grajeda JP; Tagliabue E; Iorio MV; Hidalgo-Miranda A
    Mol Oncol; 2019 Apr; 13(4):909-927. PubMed ID: 30648789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.